Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Agios Pharmaceuticals, Inc.

Servier Pharmaceuticals LLC

Other

University of California

J & J Pharmaceutical Research & Development, Llc.

Les Laboratoires Servier

Zhihua Sui

Xuqing Zhang

James C Lanter

Weiqin Jiang

James J Fiordeliso

Xiaojie Li

Mark J Macielag

Nareshkumar F Jain

Nalin L Subasinghe

Raymond C Ng

Jihua Guan

Tao Liu

Giovanni Cianchetta

Dawei Cui

Anil Kumar Padyana

Zhenwei Cai

Michael Peter Winters

Vernon C Alford, Jr

Jeremy Mark Travins

Chaozhong Cai

Zenon D Konteatis

Mark James Wall

Thomas P Markotan

Heather Rae Hufnagel

Christopher M Flores

Zhixiong Ye

Michael P Wachter

Gee-Hong Kuo

Ramesh M Kanojia

Dana L Johnson

Lawrence C Kuo

Fengbin Song

William V Murray

Yue-Mei Zhang

Janeta Popovici-Muller

David F McComsey

Christopher A Teleha

Charles S Craik

Ronald K Russell

Michael P Ferro

Irwin D Kuntz

Shawn T Branum

Jingjing Ji

Jiayi Xu

Fu-An Kang

Marta Cristina Abad

Charles Kung

Alan C Gibbs

Cuifen Hou

Shawn P Walsh

Ningyi Chen

Barry Fegely

Nagy E Fawzy

David Breslin

Raymond A Ng

Paul R Ortiz De Montellano

Guangning Ma

Samuel K Reznik

Mingzong Li

Weigin Jiang

Patricia S Caldera

Juan C Alvarez

James De Voss

Rafael Salto

Dianne L DeCamp

Lilia M Bab E

Paul S Furth

Michael Reuman

Boyo Zhao

Peng Liu

Matthew Medeiros

Shubao Zhou

Nalin Subasinghe

Vernon C Alford

Jr Vernon

Fu An Kang

Heather Rae Hufnagal

James J Johnson&JPharmR& D Llc Fiordeliso

Weiqin Johnson&Johnson Pharm R& D Llc Jiang

Jr Alford C Vernon

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R, R, R, R, R, R, and Q are as defined herein.

Pyruvate kinase activators for use in treating blood disorders

The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein R, R, R, R, and Rare defined herein.

Inhibitors of cellular metabolic processes

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein.

Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein.

Pyruvate kinase modulators and use thereof

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R, R, R, R, R, R, and Q are as defined herein. 

The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning. 

Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer

Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein. 

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein. 

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Benzo-fused heterocyclic derivatives useful as agonists of GPR120

The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R, G, and Q are defined herein;and wherein R, R, R, Rand G, are defined herein.

GPR120 agonists for the treatment of type II diabetes

Growing community of inventors

Norristown, PA, United States of America

Zhihua Sui